PimedBio
-
ABOUT US
About Us
We create new treatments
based on cutting-edge approaches. -
PLATFORM
Platform
We create new treatments
based on cutting-edge approaches. -
PIPELINE
Pipeline
We create new treatments
based on cutting-edge approaches. - PR
-
CAREER
CAREER
We create new treatments
based on cutting-edge approaches.
Based on innovative scientific achievements,
Pimedbio's first-in-class drugs
Pimedbio's first-in-class drugs
- About Us
- History
History
Changing the standard of cancer treatment by bringing Korea’s 1st immune-oncology drug
2025
- 02
- Selected for the KDDF Regulatory Affairs (RA) Support Program under the National New Drug Development Project
2024
- 11
- Selected for the Scale-up TIPS Program for High-Growth Startups (Ministry of SMEs and Startups)
- 11
- Selected for the Academia-Industry Collaborative New Drug Development Support Program
- 07
- Selected for JLABS Korea
- 02
- Registered Russian patent (anti-cancer agent targeting cancer stemness)
2023
- 12
- Selected for the SME Overseas Marketing Support Program by the Ministry of SMEs and Startups
- 12
- Chosen as one of the Top 10 Outstanding Projects among 347 projects in the National New Drug Development Project(KDDF)
- 11
- Bronze Prize at the KIT Technology Commercialization and Investment Promotion Competition
- 11
- Registered Australian patent (anti-cancer agent targeting cancer stemness)
2022
- 08
- Registered domestic patent
- 06
- Selected for the Market Expansion-Type Support Program under the SME Technology Innovation Development Project
- 03
- Selected for the Lead Compound Support Program under the National New Drug Development Project
2021
- 11
- Selected for the Non-clinical Support Program under the National New Drug Development Project(KDDF)
- 03
- Relocated to Seoul National University Bundang Hospital Healthcare Innovation Park
- 01
- Filed PCT patent (related to anti-cancer agent targeting cancer stemness)
2020
- 12
- Certified as an INNO-BIZ (Innovative SME) company
- 09
- Selected as a TIPS-recommended startup team
- 07
- Selected for the BIG3 Innovation Sector Support Program
- 04
- Selected for Infectious Disease Prevention and Treatment Technology Development Project (Ministry of Health and Welfare)
- 04
- Selected for One-Stop Support Program for Future Medical Industry at Advanced Medical Complex
- 01
- Filed domestic patent (related to anti-cancer agent targeting cancer stemness)
2019
- 10
- VC funding
2018
- 11
- Certified as a venture company
- 05
- Registered exclusive license for patent implementation
2017
- 12
- Relocated to Institut Pasteur Korea
- 11
- Selected for Bio Core Facility Construction Project
- 04
- Established an in-house corporate research institute
- 03
- Company founded
